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lnterleukin-6 Reduces Cartilage Destruction 
during Experimental Arthritis
A Study in lnterleukin-6-Deffcient Mice
Fons A. J. van de Loo,* Sandra Kuiper,* 
Frank H. J. van Enckevort,+ Onno J. Arntz,* 
and Wim B. van den Berg*
From the Departments of Rheumatology* am i
Hnducrinologv? University Hospita j Nijmegen, Nijmegen, 
The Netherlands
Using interleukin (II) -6-clefident (IL-6<>A>)  mice 
or wild-type mice, we investigated the controver­
sial role o f  IL-6 in joint inflammation and carti­
lage pathology during zymosan-induced arthri­
tis (ZIA). Monoarticular arthritis was elicited by 
inject ion o f  zymosan into the right knee jo in t 
cavity. Production o f  IL-1, tumor necrosis fac tor  
(TNF), IL-6, and nitric oxide by the inflamed knee 
iv as assessed in washouts o f  joint capsule spec­
imens. Plasma corticosterone tv as measured us­
ing a radioimmunoassay. Proteoglycan synthe­
sis was assessed using [3*S]sulfate incor­
poration into patella s ex viva Join I swelling was  
quantified by jo in t uptake o f  circulating 99n/Tech­
netium pertechnetate . Histology was taken to
join t cavity corrected the IL-6 dej'iclency and sig- 
nifleant ly reduced cartilage destruction* Inflam­
mation was more chronic in the wild-type mice, 
and these mice also showed a higher prevalence 
f o r  osteophyte form ation . In ZIA, IL-6 plays a 
dual role in connective tissue pathology>, reduc­
ing proteoglycan loss in the acute phase and 
enhancing osteophyte formation in the chronic 
ph ase . The latter could be related to the more 
s e vere j  o hit infla mm a tio n a s s een in th e norma I 
(IL-6-producfng) animals during the chronic 
ph ase  o f  arthritis, (Am J  Pathol 1997,
151:177-191)
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age. Zymosan caused a rap id  increase in articu- 
lar IL-1, IL-6, TNF, and NO levels. Except f o r  IL-6, 
the released amounts and time course o f  these 
mediators were comparable in the II-6-deficient 
mice and the wild-type mice. Elevated plasm a  
corticosterone levels were measured during the 
f irs t day o f  arthritis in both strains. At day 2 o f  
ZIA, joint inflammation (joint swelling and cell 
exudate) in IL-6-deficient mice was comparable 
with that in the wild-type mice* The marked sup­
pression o f  chondrocyte proteoglycan synthesis defense, regulaling cellular and humoral immune ro­
an d  p  roteoglyca n degra da lio n i v e re o n th e a ve i *- 
age higher in the II - 6-defi ci en I mice. Together 
this resulted in a more pronounced proteoglycan  
depletion in the I 1-6-deficient mice as compared  
with the wild-type mice during the f ir s t  week o f  
arthritis. Inject ion o f  recombinant IL-6 into the
Interleukin (IL)-6 is a glycosylated polypeptide of 
approximately 26 kd made by lymphoid and nonlym­
phoid cells. It belongs to a family of proteins with 
overlapping functions: leukemia inhibitory factor, on- 
costatin M, ciliary neurotrophic factor, and IL-11. The 
IL-6 receptor consists of two subunits, the «-chain, 
with the IL-6 binding site, and the signal-transducing 
/3-chain (gp130). The gp130 receptor is shared by all 
members of the IL-6 family, which may explain why 
they have many activities in common.1
IL-6 is present in large quantities in synovial la­
vage of patients with arthritic disorders."1 7 In rheu­
matoid arthritis (RA), synovial fluid IL-6 exceeded the 
plasma IL-6 levels in these patients.8 Synovial fibro­
blasts and the articular chondrocytes are identified 
as the main IL-6 producers in the inflamed jo in t/’ 
IL-6 is a pleiotropic mediator and is thoughl to be 
involved in both systemic and local events in the 
arthritic patient. IL-6 plays an important role in host
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sponses, in particular, B cell maturation into plasma 
cells.14 ' 16 Furthermore, IL-6 is a potent inducer of 
acute-phase protein synthesis in hepatocytes,17 and 
increased serum IL-6 levels correlated with an en­
hanced acute-phase protein response in RA pa­
tients.1,8, 18 At the local level, IL-6 promotes differen­
tiation of macrophages and is an accessory protein 
in T cell activation and antibody secretion,1'”3,19,20 
which suggests that IL-6 is at least involved in some 
features of the joint pathology. On the other hand, 
IL-6 can induce IL-1 receptor antagonist, soluble 
tumor necrosis factor (TNF) receptors and tissue 
inhibitor of metalloproteinases (TIMP) in articular 
cells21,32 and reduce TNF production,^3 which sug­
gests that IL-6 may reduce joint pathology. Some 
studies reported that IL-6 levels correlated with dis­
ease activity,"1,10 whereas others reported that the 
increase in serum IL-6 levels coincided with clinical 
improvements.2*1 Furthermore, a recent study 
showed that there was no correlation with radiologi­
cal progression of joint damage.18 There is, how­
ever, no direct evidence that IL~6 may play a role in 
the pathogenesis of RA. Studies in animal models 
may shed light on the ambiguous role of IL-6 in 
arthritis.
Recently we performed a study using IL-6 neu­
tralizing antibodies in antigen-induced arthritis 
and failed to demonstrate a role for IL-6 in inflam­
mation and cartilage destruction in this model.85 
Proteins of approximately 60 kd are unable to pen-
etrate the cartilage matrix, making it unlikely that 
chondrocyte-derived IL-6 was blocked by the 
150-kd large antibodies. For this, we couldn’t con­
clude that IL-6 was not involved in the observed 
cartilage destruction. Recently, several groups de­
veloped mice with a disrupted IL-6 gene by ho­
mologous gene recombination to study the in vivo 
role of IL-6 in bacterial and viral infection, fever 
response, and bone r e s o r p t i o n . W e  chose to 
study the effect of IL-6 deficiency on the local 
events of arthritis, ie, joint inflammation and carti­
lage destruction. It is clear that these mice exhibit 
an impaired immune response.127 For this, the zy­
mosan-induced arthritis (ZIA) model was chosen, 
as the inflammation was not immunologically me­
diated.35 It was found that the onset was compa­
rable in the IL-6-deficient mice, their wild-type con­
trols (C57BI/6X 129Sv), or the C57BI/6 mice. We 
clearly demonstrated that, in the arthritic IL-6-de- 
ficient mice, cartilage destruction was more pro­
nounced, whereas fewer animals developed os­
teophytes as compared with the wild-type mice.
Materials and Methods
Animals
Homozygous IL-60/0 and wild-type (C57BI/6X129/ 
Sv)F2 mice were obtained from M. Kopf (Basel, Swit­
zerland) and bred in our own animal facilities, as 
were the C57BI/6 mice. Mice were housed in filter- 
top cages under standard pathogen-free conditions 
and fed a standard diet and acidified tap water ad 
libitum. At the age of 8 to 10 weeks they were used in 
the experiments.
Recombinant Cytokines and Antibodies
Purified and biologically active mature murine re­
combinant IL-1 a, cloned in Escherichia coh\ was gen­
erously donated by I. G, Otterness (Pfizer Central 
Research, Groton, CT), and bioactivity was checked 
in a bioassay. Purified murine recombinant IL-6 was 
a gift from G, Ciliberto (I.R.B.M., Rome, Italy)
Control o f IL-6 Deficiency
The IL-6 gene was disrupted in the second exon by 
insertion of a neo cassette.*7 Loss of wild-type IL-6 
messenger RNA was confirmed by reverse tran­
scriptase polymerase chain reaction (RT-PCR) using 
primers bridging the insertion: 5' primer 5'TCT GCA 
AGA GAG TTC CAT CCA 3' and 3' primer 5'GCA 
AGT GCA TCA TOG TTG TTC 3 ',33 purchased from 
Pharmacia Biotech (Roosedaal, The Netherlands). 
Controls were included for a possible bypass of IL-6 
by IL-11. Sequences of the primers for IL-11 were 
upstream (5 \ 5'CTG TGG GGA CAT GAA CTG TG 
3') and downstream (3', 5'AGC CTT GTC AGC ACA 
CCA G 3'). Messenger RNA from cartilage or syno­
vial tissue, isolated with TRIzol reagent according to 
the protocol of the manufacturer (Life Technology, 
Breda, The Netherlands), was reverse transcribed to 
cDNA using oligi-dT primers by standard protocol. 
One-twentieth of the cDNA was used for one PCR 
reaction of 35 cycles: denaturation at 92°C for 1 
minute and annealing at55°C for 1 minute, followed 
by elongation with Taq DNA polymerase (Life Tech­
nologies) at 72°C for 1 minute. The expected PCR 
products of IL-6 and IL-11 were 239 and 300 bp, 
respectively. This control was performed regularly 
during breeding of the animals. In cartilage obtained 
from IL-60/0 mice, no IL-6 mRNA was detected, 
whereas IL-6 mRNA was present in cartilage from 
IL-6 17 ,‘ mice, and marked enhancement was found 
after IL-1 challenge. There was no evidence of en­
hanced IL-11 expression in cartilage from IL-60/0
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mice. Second, culture supernatant of articular carti­
lage was checked for IL-6 bioactivity using the B9 
assay, and no bioactive IL-6 was found in condi­
tioned medium of cartilage cultures from IL-60/0 
mice.
Zymosan-Induced Arthritis
A homogeneous suspension of 30 mg of zymosan A 
{Saccharomyces cerevisiae), dissolved in 1 mi of en- 
dotoxin-free saline, was obtained by boiling twice 
and sonic émulsification. Arthritis was induced by 
intra-articular injection of 180 ¡¿g of zymosan along 
the suprapatellar ligament into the joint cavity. The 
contralateral knee joint received an equal amount of 
saline (6 y,I) and served as a within-animal control.
Assessment of Joint Swelling
Animals were injected subcutaneously with 10 fxCi of 
99mTechnetium pertechnetate (99mTc) in 0.2 ml of 
saline in the neck region. After 15 minutes, mice 
were sedated by intraperitoneal injection of 4.5% 
chloral hydrate, 0.1 ml/10 mg of body weight. The 
accumulation of the isotope due to the increased 
blood flow and edema in the knee was determined 
by external gamma counting and expressed as the 
ratio of the 99mTc uptake in inflamed over contralat­
eral knee joint. A ratio higher than 1.1 indicates joint 
swelling.
Assessment of Cytokine Production by 
Arthritic Joints
Patellas were dissected with surrounding soft tissue, 
consisting of the tendon and synovium, in a stan­
dardized manner. Each patella was incubated in 200 
/xi of serum-free RPMI 1640 for 1 hour at 37°C; there­
after, medium was changed and incubated for an­
other 24 hours. Both 1- and 24-hour culture super- 
natants were stored at ~7Q°C preceding cytokine
and nitrite measurements, respectively.
Assessment of Cytokines in 1 -Hour 
Washouts of Knee Joint Capsule 
Specimens
IL-1 activity was measured in the one-stage prolifer­
ation assay as described by Gearing et al.36 The 
murine thymoma cell line EL-4 NOB-1 (ECACC, Por- 
ton Down, Salisbury, UK) was used as an IL-1-spe­
cific cell producing IL-2 in response, in combination 
with the IL-2-sensitive CTLL2 cells (ECACC). The
cells were plated out in concentrations of 1 x  10*7 
well NOB1 cells and 4 x  103/wel! CTLL cells in RPMI 
supplemented with 5% fetal calf serum for 21 hours.
IL-6 activity was determined by a proliferative as­
say using B9 cells. Briefly, 5 x  103 B9 cells in 200 julI 
of 5% fetal calf serum/RPMI 1640 per well were 
plated in a round-bottom microtiter plate and incu 
bated for 3 days using human recombinant IL-6 a 
standards. At the end of the incubation (both IL-1 
and IL-6 assay), 0.5 /xCi of [Ml-
«
activity, 20 Ci/mmol; Dupont NEN, Boston, MA) was 
added per well. Three hours later, cells were har­
vested and thymidine incorporation (NOB1 cells are 
thymidine kinase deficient) was determined. The de­
tection limit of the IL-1 assay was 0.1 pg/rnl murine 
recombinant IL-1 and for the IL-6 assay was 1 pg/mL 
TNF in culture supernatants was measured in du­
plicate by non-equilibrium radioimmunoassay (RIA) 
as described elsewhere.37 In short, standards and 
culture supernatants were diluted in a RIA buffer 
containing 60 mmol/L Na^HPO^H^O, 12 mmol/L 
sodium EDTA; 0.02% sodium azide, 0.25% bovine 
serum albumin (RIA grade, Sigma Chemical Co., St. 
Louis, MO), 0.1% Triton X-100, and 250,000 kal- 
likrein-inactivating units of aprotinin (Bayer, Le­
verkusen, Germany), pH 7.4. A 100-/uJ volume of an 
appropriate rabbit anti-TNF antiserum dilulion in RIA 
buffer was added to 100 /xl of samples and slarv 
dards and kept on ice. After vortexing, the tubes 
were incubated for 24 hours at 4°C. Subsequently, 
100 ¡xI of the appropriate 1:,|,Mabeled TNF-a contain­
ing approximately 10,000 cpm was added to each 
tube, and incubation was continued for another 24 
hours at 4°C. To separate bound and free tracer, 760 
/xl of RIA buffer containing 9% (w/v) polyethylene 
glycol 6000 (Merck Diagnostics, Darmstadt, Ger­
many) and 3% (w/v) goat anti-rabbit serum were 
added. The tubes were incubated for 20 minutes at 
room temperature and then centrifuged at 1500 x <;/ 
for 15 minutes. Supernatants were discarded can 
fully and quickly drained on absorbent paper. Re 
maining radioactivity was counted in a gamma 
counter. The radioactivity in control lubes (the non­
specific binding activity) was subtracted from sam­
ples and standards.
&
Nitrite Measurements in 24-Hour Washouts 
of Knee Joint Capsule Specimens
The medium concentration ol NO,, (a stable break­
down product of NO) was determined by Qriesa 
reaction using NaNOj, standards. Th© Griess re­
agent consisted of 0.1% naphlylethylene diamine
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dihydrochloride, 1:1 diluted with 1.0% sulfanilamide 
in 5% H3P04. Briefly, 100 /xl of conditioned medium 
was mixed with 100 ¿¿I of Griess reagent in a flat- 
bottom microtiter plate and adsorbance read at 545 
nm using an ELISA plate reader.
Blood Sampling and Corticosterone 
Measurements
Mice were anesthetized by ether inhalation, and 
blood samples were collected within 5 minutes in dry 
lithium/heparin glass tubes and centrifuged at 
1500 x g for 10 minutes at 4°C. Plasma was sepa­
rated and stored at -20°C  until assayed, Corticoste­
rone was measured by RIA as described by Sweep 
et al.38 Briefly, plasma corticosterone was extracted 
with 7.5 ml of dichloromethane (Baker, Deventer, The 
Netherlands). The water phase was discarded and 
the dichloromethane phase was evaporated. The 
residue was dissolved in 2 ml of 0.2% ethylene gly­
col/water, and the concentration of corticosterone in 
the eluate was measured by RIA using an antiserum 
raised in sheep against a B-21-hemisuccinate-bo- 
vine serum albumin conjugate. Corticosterone tracer 
([1a,2a-/\/-3H]corticosterone; Amersham, Little Chat- 
font, UK) was used in the extraction and in the RIA 
procedure. The sensitivity of the assay was 25 to 45 
fmol/tube. The intra- and interassay coefficients of 
variation were 10 and 16.7%, respectively.
Assessment o f Chondrocyte Proteoglycan 
Synthesis
Patellas were dissected with a minimal amount of 
adjacent soft tissue and placed in RPMI 1640 sup­
plemented with gentamicin (50 mg/L), L-glutamine (2 
mmol/L), and 40 ¡xCl of [35S]sulfate, At the end of the 
3~hour incubation period, nonincorporated free ra­
diolabel was removed by thorough washing of the 
patellas in saline (three times for 10 minutes each) 
and fixed overnight in 10% formalin. After decalcifi­
cation in formic acid (5%) for 4 hours, the whole 
patellas could easily be punched out (agar gel 
punch of 1 mm diam.). The patellas were dissolved 
in 0.5 ml of Lumasolve (Lumac, Groningen, The 
Netherlands) overnight at 60°C. The 36S content of 
each patella was measured by liquid scintillation 
counting and expressed as counts per minute 
(cpm). More than 95% of the radiolabel was incor­
porated into the glycosamlnoglycans of proteogly­
cans.39,40 Data are represented as total incorpora­
tion of [35S]sulfate or as a ratio of right over left knee 
(wilhin-animal control value) as paired values.
Assessment of Cartilage Proteoglycan 
Degradation
Radioactive sulfate (50 /¿Ci of [35S]sulfate/200 /xl of 
safine) was injected into the peritoneal cavity 1 day 
before arthritis induction.40 At day 2 of arthritis, pa­
tellas were dissected and processed for liquid scin­
tillation counting as described in the previous sec­
tion.
Histological Processing and Analysis of 
Knee Joints
Knee joints were dissected, fixed, decalcified, dehy­
drated, and embedded in paraffin. Standard frontal 
sections of 7 /xm were prepared and stained with 
safranin-0 and counterstained with fast green. Serial 
sections of the whole knee joints were scored by two 
independent blinded observers. Cartilage depletion 
was scored using a linear scale from 0 (normal sa- 
franin-0 staining, indicating no depletion) up to 3 
(complete loss of safranin-0 staining, indicating full 
depletion. Furthermore, the presence of chondro- 
phytes (cartilaginous tissue) and osteophytes (ossi­
fied tissue) adjacent to the patellas was evaluated 
histologically and the incidence was determined in 
the different mouse strains.
Statistical Analysis
Data are expressed as mean values ± SD unless 
stated otherwise. Statistical significance was tested 
using the Wilcoxon's rank sum test or with the Stu­
dent's f-test as stated.
Results
Zymosan-Induced Cytokine Release in 
Murine Knee Joints
An intra-articular injection of zymosan triggers the 
release of the pro-inflammatory cytokines IL-1, 
TNF-a, and IL-6 by the synovial joint capsule (Figure 
1, A-C). No IL-1 and IL-6 was present in washouts of 
tissues taken from normal joints. In contrast, consid­
erable amounts of TNF were found in these control 
supernatants, although it was not biologically active. 
The largest amounts of IL-1 and IL-6 were found in 
washouts of tissues from joints taken 3 and 6 hours 
after zymosan injection, respectively. At these time 
points, higher amounts of immunoreactive TNF were 
also measured in these washouts. Although IL-6 lev­
els exceeded those of IL-1 and TNF at the molar
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Figure 1. //.-/, TNF. lf.~(\ anti NO release on vivo by specimen t f  the 
articular synovial capsule dissected during zymosan-induced arthri­
tis. fhitellas with adjacent soft tissue wore dissected in a standanllzod 
manner to obtain laige specimens of'synovia. Patei/as trero incubated 
in 200 ¡xl ofttPM Ifor i hour at room temporal tt re followed by 24 hoars 
at M °C  for assessment of If.~ I by N( )I i/C.I'Ll. proliferation assay (A), 
TNF by id A CB >, IL-6 by B9 proliferation assay (C). and NO by (>riess 
reagent (D ), as described in Materials and Methods. Data represent the 
mean rat tie of]four paiellas per time point. ¡L~i and NO lords between 
If.-6 ' ' '  and if.-ft*"" nuce wore not significantly different. 11.-6 in con­
ditioned media of paiellas from  ll.-6ut‘ mice cotdd not be detecteil 
using the BV assay.
base, IL-1 and TNF release was IL-6 independent as 
became evident from zymosan injections into lL-6- 
deficient mice (Figure 1).
increased Nitric Oxide Release after 
Zymosan injection
Increased nitrite levels were measured In the 24-hour 
culture supernatants of synovial joint capsule spec- 
imens taken 3, 6, and 24 hours after zymosan Injec­
tion (Figure 1D). Levels were not significantly differ­
ent between the IL-6-deficient mice and the wild- 
type C57BI/6 mice, suggesting that IL-6 also was not 
involved in NO production In zymosan-injected 
knees.
Plasma Corticosterone and IL-6 Levels 
during Zymosan-Induced Arthritis
Increased plasma corticosterone levels were mea­
sured at 3 and 6 hours after induction of arthritis in 
the wild-type mice (Table 1). Corticosterone values 
returned to baseline within 24 hours after zymosan 
injection. Plasma IL-6 levels were also raised 3 and 6 
hours after zymosan Injection intra-articularly and 
returned to baseline at 48 hours in the wild-type 
mice. By comparison, the plasma IL-6 levels in the 
wild-type mice were far below the amounts found in 
the washouts of inflamed synovial joint capsule 
specimens of these animals, but both reached 
higher values at 6 hours and already markedly de­
clined at 24 hours after arthritis induction (Table 1; 
Figure 1C),
Time course and plasma levels of corticosterone 
in the IL-6-deflcient mice were indistinguishable from 
the response in the wild-type mice (Table 1). The 
corticosterone response seemed to be IL-6-indepeiv 
dently regulated as no IL-6 was detected in these 
plasma samples (Table 1).
Zymosan-Induced Joint Inflammation
Enhanced blood flow and plasma extravasation 
(edema) resulted in an increased uptake of circulat­
ing WMnTc isotope by the inflamed knee joint. Joint 
swelling at day 2 of ZIA was not different between the 
IL~6~deficient mice, the wild-type mice, and the 
C57BI/6 strain (Table 2), At day 4 of ZIA, joint swell­
ing had subsided significantly more in the IL-6-defi- 
cient mice as compared with the IL-6'7' strains (Ta­
ble 2).
Enhanced Cartilage Destruction in IL-6- 
Deficient Arthritic Mice
Marked inhibition of chondrocyte proteoglycan syn­
thesis and accelerated proteoglycan breakdown
182 van de Loo et ai
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Table 1. Plasma Corticosterone and IL-6 Levels during Arthritis
Time of arthritis
C57BI/6 (IL-6l7+) mice C57BI/6 x 129Sv (IL-60/0)
(hours) Corticosterone (nmol/L) IL-6 (ng/ml) Corticosterone (nmol/L) IL-6 (ng/ml)
0 123 ±  86 0.23 + 0.06 266 + 62 0.13 ± 0.00*
3 894 ±  152 2.56 + 1.02 789 ± 77 0.22 + 0.06
6 741 ± 295  6.14 ± 2.36 651 + 196 0.22 + 0.06
24 282 ± 54 1.02 ± 0.72 166 + 41 0.16 + 0.08
48 161 + 101 0.32 + 0.13 159 + 177 0.13 + 0.00
Corticosterone was measured by RIA as described in Materials and Methods. Plasma corticosterone levels in untreated mice ranged 
between 20 and 400 nmol/L, The values at 3 and 6 hours were not significantly different between normal and the IL-6-deficienl mice. IL-6 
was measured using a bioassay as described in Materials and Methods. The number of animals per time point evaluated was four per 
mouse strain.
*Detecllon limit for nonspecific stimulation of B9 cells using plasma.
was measured in patellas at day 2 of arthritis (Table 
3). Both inhibition of proteoglycan synthesis and 
breakdown were moderately but significantly higher 
in the lL-6-deficient mice. The combined effect was a 
more pronounced loss of cartilage giycosaminogly- 
cans in the IL-6-deficient mice (-2 8  ±  10%) as 
compared with the wild-type mice ( - 7  ± 9%) at day 
2 of arthritis.
IL-1 -Induced Proteoglycan Synthesis 
Suppression and Degradation
We further evaluated the chondrocyte responsive­
ness to IL-1 in normal and IL-6-deficient mice. Mu­
rine recombinant IL-1 a was injected intra-articularJy, 
and pateiJar proteoglycan synthesis and degrada­
tion were measured 24 hours later. IL-1 caused a 
distinct inhibition of synthesis and only a moderate 
breakdown of proteoglycans (Table 4). In the i L-6- 
deficient mice, IL-1-induced suppression and deg-
radation were not different, suggesting that the chon­
drocytes in these mice were not more vulnerable for 
IL-1 and that IL-6 has no major role in these pro­
cesses.
Role of IL-6 in Joint Pathology during 
Zymosan-Induced Arthritis
Histological sections of whole knee joints showed 
severe inflammation at days 2, 4, and 7 after zymo­
san injection, At day 2, plasma exudation was a 
prominent feature (Table 2), and large numbers of 
polymorphonuclear neutrophils entered the joint 
space (Table 5; Figure 2). At day 7 of arthritis, syno­
vitis became the prominent inflammatory feature in 
the wild-type mice and synovitis was less severe in 
the IL-6-deficient mice (Table 5). Cartilage proteo­
glycan depletion was already evident at day 2 of 
inflammation and progressed into severe loss at day 
7 of inflammation (Table 5; Figure 2). At day 2 of the
Table 2. joint Swelling in Zy mosa n-Indu ceci Arthritis
99m Tc uptake (R/L ratio)
Time (day) C57B1/6 mice (IL-647')  C57BI/6 X 129Sv (IL-60/0) C57BI/6 X 129Sv (IL-6'7 ' )
2 1.57 ± 0.09(13) 1.53 ± 0.20 (18) 1.56 ± 0.17 (14)
4 1.18 ± 0.09(13)* 1.06 ± 0.10(13) 1.15 ± 0.09 (13)1
Joint swelling is expressed as a ratio of uptake by the arthritic joint (R) over the normal contralateral knee joint (L). Joint swelling 
was significantly different from Ihe C57BI/6 x  129Sv (JL-6CV°) mice: *P < 0.01; •P < 0.05 {Student’s i-test). The number of animals per 
group is indicated In parentheses.
Table 3. Proteoglycan Turnover during Arthritis in Normal and lL-6-Deßcieul Mice
Mouse strain
C 57 BI/6 (IL-6+/+)
C57BI/6 X  129Sv (IL-60/0) 
C57BI/6 X  129Sv (IL-6 1/1 )
Proteoglycan synthesis Proteoglycan breakdown
Ratio
(cpmR/cp n \)
Inhibition
(%)
Ratio
(cpmR/cpmL) Enhanced loss (%)
0.42
0.33
0.42
± 0.11* (9) 
± 0.07 (9) 
± 0.19 (6)
58
67
58
0.66 ± 0.07* (16) 
0.57 ± 0.09(14) 
0.64 ± 0.08* (16)
34
43
36
Proteoglycan synthesis and proteoglycan degradation were measured at day 2 of ZIA as described in Materials and Methods and 
expressed as the ratio of [:u'S]sulfate content (cpm) in Ihe arthritic knee joint (R) over the normal contralateral joint (L). Number of animals 
per group is indicated in parentheses.
*Values are significantly different between IL-6-deficient (0/0) and the lL-6-producing (+ /+ ) mouse strains: P <  0.05 (Student's t-test).
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Table 4. ¡i/fcct oj II-I Injection on Proteoglycan Turnover in IL-6-Deficíenl Mice and Mice
Proteoglycan synthesis Proteoglycan breakdown
Mouse strain
Ratio
(cpmR/cpn\) Inhibition (%)
Ratio
(cpmR/cpm,) Enhanced loss (%)
C57BI/6 (IL-e17” )
C57BI/6 X 129Sv (IL-60/0)
0.59 + 0.07 (7) 
0.59 ± 0.13 (7)
41
41
0.91 + 0.13 (7) 
0.89 + 0.08 (7)
9
11
«, V  *É ~ *■ iJ i ‘M  l í . ”
Proteoglycan synthesis was measured at day 1 after injection, and proteoglycan breakdown was measured at day 2 after injection of 10 
rig of murine recombinant IL-1«. Expression of proteoglycan synthesis is as explained in Table 3. Number of animats per group is indlaiKKl 
in parentheses,
joint inflammation, cartilage proteoglycan loss was 
significantly higher in the IL-6-deflcient mice as com­
pared with the IL-6+/+ mice strains. This difference in 
proteogiycan loss was still present at day 7 of arthri­
tis, although the ongoing Inflammation became more 
severe in the wild-type mice (Table 5),
Effect of IL-6 Administration to IL-6-Deficient 
Mice on Zymosan-Induced Arthritis
To prove the ameliorating role of IL-6 on cartilage 
destruction during arthritis, knockout mice received 
recombinant IL-6 iocaiJy. Recombinant IL-6, either 
applied as a co-injectlon with zymosan or injected 3 
hours after the zymosan injection, reversed the en­
hanced cartilage destruction in these knockout mice 
(Table 6). IL-6 supplementation did not suppress 
joint inflammation, and this again proves that the 
onset of inflammation was IL-6 independent.
Osteophyte Formation in Zymosan-Induced 
Arthritis
The first signs of osteophyte formation (chondro- 
phytes) were seen at day 7 of arthritis, adjacent to 
the patellas (Table 7). Of 24 normal mice, 13 devel-
oped significant osteophytes, compared with only 2 
of 26 IL-6-deficient mice. At day 14, the incidence 
was 6 of 6 mice in the normal group and 3 of 6 mice 
in the IL-6-deficient group. The total number of os­
teophytes developed at both lateral and medial sites 
of the pateila (Figure 2) was also higher in the IL-6 *v 1 
group as compared with the IL-6-deficient group 
(Table 7).
Discussion
Using IL-6-deficient (lL-60/0) mice or wild-type mice, 
we provided direct evidence that IL-6 was involved 
in cartilage pathology in an experimental model of 
arthritis. Cartilage proteoglycan depletion in the early 
phase of ZiA was significantly higher in the IL-6- 
deficient mice, whereas joint inflammation was com­
parable between the strains, suggesting that IL-6 
ameliorates cartilage proteoglycan destruction. Fur­
thermore, IL-6-deficient mice developed fewer num­
ber of osteophytes in the chronic phase of arthritis. 
This is probably related to the significantly milder 
joint swelling and synovitis from day 4 of arthritis in 
the IL-6-deficient mice as compared with the wild- 
type mice.
Table 5. Histological lit >ciin ct thru of Xytmm ii-tndi teed Arthritis in Normal and IL-6-Deficit* ni Mice
Group
Day 2 ZIA 
C57BI/6 
C57BI/6 
C57BI/6 
Day 4 ZIA 
C57BI/6 
C57BI/6 
C57BI/6 
Day 7 ZIA 
C57BI/6 
C57BI/6
(IL-6 1/1 )
X 129SV (ÍL-60/ü) 
X 129Sv (IL-6 171 )
(IL-6'/'")
X 129SV (IL-60/°) 
x  129SV (IL-6 W l)
x  129SV (IL-60/0) 
X 129Sv (IL-61/1 )
Cellular infiltrate
2.23 ± 0.86 (40) 
2.28 + 0.99 (40) 
2.32 ± 0.95(19)
1.21+0,27 (7) 
0.93 + 0.35 (7) 
1.00 + 0.50 (7)
1.44 + 0.85 (26) 
1.90 ± 0.90 24)
,^ —  ji i s ft, , _ ,
Proteoglycan depletion
n h .is** *+* '*
Patellar cartilage Femoral cartilage
• . •  .  I , -
0.65 i  0.46* (40)
1.61 ± 0.73 (40)
0.92 ± 0.48* (19)
1.50 ± 0.71* (7)
2.29 ± 0.39 (7)
1.25 ± 0.55* (7)
2.08 ± 1.03 (26)
1.52 ± 1,05nR (24)
1.05 ± 0.69* (49) 
1.90 ± 0,85 (46) 
1.30 + 0.71* (25)
1.79 ± 0.64
2.43 ± 0.45
1.43 ± 0,61
(7)
(7)
(7)
2.15 ± 1.08 (26) 
1.63 ¿ 0.98n!i (24)
Serial histological sections of knee joints were scored by blinded observer. For joint inflammation, al day 2 and 4, the extent of oxudatod 
neutrophils was scored, and at day 7, synovitis was scored. Cartilage depletion was scored as Joss of safranin-0 staining. A maximal scoro 
of 3 indicates no staining of the superficial cartilage layers (see Figure 20). Cartilage depletion was statistically tested between IL-Ci- 
deficient (0/0) and the IL-6-producing (+ /+ ) mouse strains: *P < 0.01 (significantly different using the Wilcoxon rank sum test), ns, not 
significant. Number of animals per group is indicated in parentheses.
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A Cross-section knee joint
FEMUR
B, Bone; BM, Bone Marrow;
C, Cartilage; GP, Growth Plate;
L, Lining; S, Synovium.Photograph 
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Figure 2. 11ist< >k>g leal section of normal knee JoitUsiB and K) and knee joints injected it'ftb zymosan (G /oJ). Serial sect Ions t ten* stained triti) sa fran ino  
and seared in a hii tided Jash ion. A: Schematic tvptvseniaiion ofthe Jbmoro/>a(eifar tvgion ( fa  knee joint section, indicating (be i afferent articular tissues 
and the site taken f ir  the higher magnification insefs (Cl and D1 ), Sa frani ti-O statuiti# tras tost in the superficial cartilage layers In thefeuioro/)ateffar 
area at day 2 of XJA in the CS7IW<i mouse (C, C1 ) and mis more ¡mmouu ceil in the HAi-rfeficienl mouse ( D, D1 ). This um  also seen in ihe Jen torot if)iat 
atva (E, wild type; F, ll-6-ilefictent mice). Note that ihe presence of neutmphils in the joint catity and syuoriutu teas similar in hath the wild-type and 
lK-6-iicficietit mouse. At day 7 of ZIA. cartilagejmiieogtycan depletion was nnuv pmuonnceil (G ) cntd still higher iti the I!,( ^deficient m/a'( H ). Osteophytes 
uvtv present at day 14 of ZiA in the C57IÌÌ/6 mousei\) us indicated hy /¿¿'arrowheads, and reduced nuntheis wetvseeu in (he I l-iy deficient mouse ( J). 
No osieo/>hy(es teetv seen in age-watched IfAi-riefictont (K) or wild-type mice. Magnification, X too.
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Figure 2.
Opsonized zymosan is a potent trigger for IL-1, 
TNF, and IL-6 synthesis in murine macrophages in 
vitro and in vivo.41"43 Intra-articular injection of zymo­
san also triggered the release of these pro-inflam- 
matory mediators locally. Comparable amounts of 
bioactive IL-1 and immunoreactive TNF were found 
in washouts of joint capsule specimens taken from 
IL-6-deficient mice and wild-type mice. This sug­
gests that IL-6 was not involved in inducing either
IL-1 or TNF synthesis. At least for IL-1, the balance of 
cytokine/cytokine inhibitors (IL-1 Ra, soluble IL-1 re­
ceptors) was not altered by IL-6. IL-1 and TNF are 
potent inducers of nitric oxide, and we previously 
demonstrated that murine recombinant IL-6 did not 
induce NO production in murine chondrocytes and 
synoviocytes.'1'1 Peritoneal macrophages obtained
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Table 6. l\JJect of IL-6 Supplementation on Zymosctrhliulucec/ Arthritis in Knockout Mice
Cartilage proteoglycan depletion
Group Cellular infiltrate Patella l-emur
Day 2 ZIA 
C57BI/6 (IL-6+/+)
C57BI/6 X  129Sv(IL-6+/+) 
C57BI/6 X 129SV (IL-60/0) 
IL-60/0; IL-6 i.a, at 0 hour 
IL-60/0; IL-6 i.a. at 3 hours
1.83 ± 0.26 
1.75 ± 0.27 
1.30 ± 0.57 
1.67 ± 0.68 
1.50 ± 0.45
0.71 ± 0.25
1.33 ± 0.68 
2.10 ± 0,55 
1.17 ± 0.52*
1.33 ± 0.68*
1.25 ± 
1.67 ± 
2.00 ± 
1.58 ± 
1.83 ±
0.61
0.82
0.61
0.58
0.61
W»Ufi
Arthritis was elicited by intra-articular (i.a.) injection of 180 ¡xq of zymosan. For local IL-6 supplementation in the knockout mice, 900 ng 
of recombinant IL-6 was either co-injected with zymosan (0 hour) or injected intra-articularly 3 hours after zymosan, Serial histological 
sections of whole knee joints {six mice per experimental group) wore scored by two blinded observers. For joint inflammation, at day 2, the 
extent of exudated neutrophils was scored. Cartilage depletion was scored as loss of safranin-0 staining, with a maximal score of 3 
indicating no staining of the superficial cartilage layers (see Figure 2C), Values of cartilage depletion were statistically tested between IL-6- 
deficient (0/0) and the IL-6-supplemented groups: *P < 0.05 (significantly different using the Wiicoxon rank sum test).
ride and interferon-7,27 suggesting that IL-6 was not 
a necessary mediator/cofactor in NO synthesis. We 
also found no effect of the IL-6 deficiency on NO 
production during ZIA (Figure 1D).
At day 2 of arthritis, joint swelling and inflammation 
was as severe in the I L-6-deficient mice as In the 
wild-type mice (Tables 4 and 5). This suggests that 
IL-6 does not play a role at the onset of inflammation. 
Treatment of mice with IL-1 and TNF neutralizing 
antibodies had only a modest effect on zymosan- 
induced inflammation,25 although their role in inflam­
mation was greater in other animal models of arthri­
tis.'15“'"19 Also in the zymosan-induced mouse 
peritonitis, administration of anti-IL-1/3 antibodies 
had no effect on mononuclear cell migration to the 
inflamed site and only partly (-40% ) reduced neu­
trophil migration.50 It remains to be seen which cy­
tokine is mediating the zymosan-induced joint in­
flammation. A possible candidate is NO. NO is a 
potent vasodilator,51 and administration of an argi­
nine analogue reduced joint swelling and neutrophil 
influx in animal models of arthritis,52“54 The NO levels 
found in washouts of joint capsule specimens taken 
during ZIA were comparable between the IL-6-defi- 
cient mice and the wild-type mice.
At later time points of arthritis, inflammation was 
less severe in the lL-6-deficient mice as compared 
with the wild-type mice (Tables 2 and 5). At this 
phase, synovitis was prominent and exudate was 
strongly reduced. We found no clear changes in the
time course of cytokine release that could explain the 
difference in joint inflammation between the mouse 
strains. The role of IL-6 is also not clear, and several 
IL-6 functions could be in place. For example, IL-6 
prolongs survival of neutrophils55 and maturation of 
macrophages.19,20 Furthermore, corticosteroids are 
potent anti-inflammatory mediators. This could be of 
importance as it was demonstrated that the IL-6- 
deficient mice showed an impaired corticosteroid 
response to TNF.29 We, however, found identical 
plasma corticosterone levels during ZIA in the differ­
ent mouse strains (Table 1), indicating that cortico­
sterone was not responsible for the difference in 
disease remission between the strains.
This study provided evidence for a modulating 
role of IL-6 in cartilage pathology. Although the sup­
pression of cartilage proteoglycan synthesis and 
proteoglycan degradation were only moderately en­
hanced at day 2 of ZIA in the IL-6-deficient mice as 
compared with wild-type mice (Table 3), the net 
effect was a more pronounced cartilage proteogly­
can depletion (Table 5; Figure 2). In comparison with 
other species, cartilage proteoglycan turnover is 
high in mice. For this, both enhanced degradation 
and reduced proteoglycan synthesis will contribute 
to this loss. In the IL-6-deficient mice, the normal 
bone turnover was significantly increased.32 If the 
cartilage proteoglycan turnover in these mice is also 
higher, then suppression of synthesis will contribute 
even more to the proteoglycan loss in these mice
Table 7. Occur re nee of Osteophytes in Zymosan-Induced Arthritis
« A # .  »
Number of Number of animals Percentage of animals 
Mouse strain Day of ZIA osteophytes with osteophytes with osteophytes
C57BI/6 X 129Sv (IL-6 '71) 7 16 13 54
14 9 6 100
C57BI/6 x  129Sv (IL-60/0) 7 3 2 8
14 4 3 50
Osteophytes developed al the lateral and/or Ihe medial site ol Ihe patella during ZIA were counted as seen on serial histological
sections of whole knee joints.
Role of IL-6 in Experimental Arthritis in Mice 187
AJPJnly 1997, Vol. 151, No, t
during arthritis. Circumstantial evidence was pre­
sented by cartilage explant cultures that addition of 
IL-6 reduced spontaneous proteoglycan release,56 
suggesting that, in the absence of endogenous IL-6, 
proteoglycan turnover might be higher.
We previously demonstrated the pivotal role of 
IL-1 but not of TNF in zymosan-induced cartilage 
pathology and proved that IL-1 was responsible for 
the suppression of chondrocyte proteoglycan syn­
thesis in this model,25 Although identical IL-1 levels 
were found during ZIA, chondrocytes from the IL-6- 
deficient mice might be more susceptible to IL-1. To 
investigate this, IL-1 was injected intra-articularly in 
both mouse strains. Substantial suppression of pro­
teoglycan synthesis and degradation of proteogly­
can was found, and the mouse strains responded to 
IL-1 alike. Whether this also holds true for TNF- or 
NO-mediated destruction remains to be examined. 
In vitro studies showed that IL-6 stimulates expres­
sion of TIMP,22 and a prechallenge with IL-6 reduces 
TNF production23 and IL-1-induced cartilage de­
struction.56 This argues in favor of a down-regulating 
role of IL-6 on cartilage pathology. Furthermore, IL-6 
played a pivotal role in the acute-phase response in 
the RA patients,17 and some of the acute-phase 
proteins, eg, cv2-macroglobulin and a1 -proteinase 
inhibitor, are known to block cartilage-destructive 
enzymes.57 In the wild-type mice, plasma IL-6 levels 
increased the first day of ZIA with an identical time 
course as found in the inflamed joints (Table 1). 
Potentially, the enhanced cartilage destruction dur­
ing arthritis in the IL-6-deficient mice was caused by 
the impaired acute-phase response as has been 
described in these mice.27,29,34 Interestingly, the ar­
ticular IL-6 levels exceeded those in plasma in RA 
patients,8 suggesting that the inflamed joint could be 
the source of circulating IL-6 during the disease.
Using IL-6-deficient mice, we were able to dem­
onstrate the ameliorating role of IL-6 in cartilage 
proteoglycan destruction during ZIA in this study. To 
exclude that the results are caused by strain differ­
ences, we used both C57BI/6 mice and wild-type 
mice and found no significant differences between 
the controls. Furthermore, most parameters as mea­
sured in this study were not significantly different 
between the knockout mice and control strains. How­
ever, the ultimate proof of the modulating role of IL-6 
on cartilage pathology is presented by the intra- 
articular application of IL-6, which ameliorated the 
cartilage destruction in the lL-6-deficient mice (Table 
6).
We do not claim that IL-6 is the only modulating 
factor operating during ZIA. Oncostatin M, another 
member of the IL-6 superfamily, also has the poten­
tial to reduce cartilage degradation by stimulating 
TIMP-1 expression in chondrocytes.58 The anti-in­
flammatory and chondroprotective action of the Th2- 
cell-related cytokines IL-4 and IL-10 are impres­
sive,59" 61 although it remains to be seen whether 
these cytokines are involved in murine ZIA as this 
model is not immunologically mediated. Of the 
growth factors, insulin-like growth factor-1 and the 
bone-morphogenetic proteins (BMPs) not only are 
constitutively expressed in cartilage and bone but 
they also promote synthesis of proteoglycans62" 65 
and may antagonize chondrocyte inhibition. Our 
data, however, clearly showed that IL-6 is an impor­
tant modulating mediator, ameliorating cartilage pro­
teoglycan destruction.
Osteophyte formation is another feature of the pa­
thology observed in ZIA, Reduced numbers of os­
teophytes were found in the IL-6-deficrent mice (Ta­
ble 7). In general, osteophyte formation is clearly 
related to the severity of inflammation and the de­
gree of cartilage destruction.66-68 This relationship 
was lost In the IL-6-deficient mice because those 
animals had increased cartilage destruction together 
with reduced joint inflammation. In the wild-type 
mice, the increased osteophyte formation could be 
ascribed to the more severe joint inflammation in the 
chronic phase of arthritis. These studies also sug­
gest that osteophyte formation probably originates 
from activation of the periosteum (site of enhanced 
[36S]sulfate incorporation) rather than from bone 
cells. Although osteoblasts are potent IL-6 produc­
ers, they barely respond to IL-6 themselves, and the 
osteoclasts are stimulated by IL-6 to resorb bone.2 
Therefore, it is unlikely that IL-6 activation of oste­
oclasts caused osteophyte formation. However, it 
remains to be seen whether IL-6 or other, possibly 
IL-6-induced, mediators activated the periosteum 
during arthritis.
We previously found that injections of transforming 
growth factor (TGF)-/31 into the murine knee joint 
resulted in marked osteophyte formation,69 More­
over, co-injection of TGF-/3 completely antagonized 
IL-1-induced suppression of proteoglycan synthesis 
in murine cartilage.70 It Is known that IL-6 Is a potent 
inducer of TGF-/3 isoforms in human articular chon­
drocyte cultures71 and in macrophages.72,73 There­
fore, reduced TGF-/3 concentrations in the inflamed 
joints of IL-6-deficlent mice may explain the reduced 
number of osteophytes and the increased suppres­
sion of proteoglycan synthesis as compared with the 
wild-type mice, and this is currently under investiga­
tion. BMP-2 is also a potent stimulator of proteogly­
can synthesis in murine chondrocytes and can in­
duce pronounced osteophyte formation in vivo.7A
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BMP-2, in contrast to TGF-/3, could not antagonize 
the lL-1-induced suppression of chondrocyte pro­
teoglycan synthesis in murine cartilage,74 which 
qualified BMP-2 as an endogenous mediator in ar­
thritis providing osteophyte formation without affect­
ing proteoglycan synthesis suppression. Reduced 
BMP-2 expression in the arthritic IL-6-deficient mice 
may also lead to a lower prevalence for osteophyte 
formation.
Preliminary results showed that three intra-articu- 
lar injections of 200 ng of human recombinant 
TGF-j32 on alternate days caused pronounced os­
teophyte formation in both IL-6-deficient and wild- 
type mice 7 days after the last injection (data not 
shown). This demonstrated that osteophyte forma­
tion per se was not impaired in the IL-6-deficient 
mice,
Some of the controversies of IL-6 in arthritis is 
probably related to the two faces of IL-6. IL-6 is 
beneficial in the early phase, reducing cartilage pro­
teoglycan Joss probably by inducing inhibitors, and 
IL-6 is detrimental in the chronic phase, mediating 
osteophyte formation probably by inducing TGF-/3.
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